Please login to the form below

Not currently logged in
Email:
Password:

Former NICE chair joins board of biotech

Sir Michael Rawlins joins board of Intra-Cellular Therapeutics

Michael RawlinsThe former chair of England's cost-effectiveness body for medicines, Sir Michael Rawlins, has made a contentious move to the US biotech Intra-Cellular Therapies as member of its board of directors.

Sir Michael was chair of the National Institute for Health and Care Excellence (NICE) from its foundation in 1999 up to April 2013, and his move from a public body to recommend medicines for use on the NHS to a private drug developer has raised some eyebrows about the potential for conflict of interest.

As reported in the Financial Times, NICE's conflict of interest code does not cover periods after retirement, although Sir Michael told the newspaper he had discussed the appointment with the permanent secretary at the Department of Health who had approved it.

“I no longer have anything to do with [NICE],” he told the FT, clarifying his future influence on the health technology assessment (HTA) body.

Dr Sharon Mates, chair and CEO of Intra-Cellular Therapies, commented on the benefits Sir Michael's experience would bring to a company looking to take its late-stage antipsychotic ITI-007 to commercial approval.

“His expertise in the cost-effectiveness of new pharmaceuticals and other issues in health economics will be invaluable to Intra-Cellular Therapies,” she said. “I look forward to working closely with Michael as we transition our clinical programmes through late-stage development and commercial approval.”

Sir Michael said he was “delighted” with his new appointment.

He said: "ITI has set itself on a course to develop outstanding new pharmaceuticals to treat CNS diseases, surely an ambitious task, but one in which I am pleased to join and help."

In addition to his former role at NICE, Sir Michael is the current president of the UK's Royal Society of Medicine.

He was also professor of clinical pharmacology and a general physician at the University of Newcastle upon Tyne.

17th May 2013

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics